Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis.
about
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in medicare patients.Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
P2860
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@en
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@nl
type
label
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@en
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@nl
prefLabel
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@en
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@nl
P2093
P2860
P1476
Polypharmacy and comorbidity a ...... erapy: a preliminary analysis.
@en
P2093
James H Lewis
Manie Juneja
Rebekah Euliano
Rohit Satoskar
P2860
P2888
P304
P356
10.1007/S10620-013-2812-9
P577
2013-08-08T00:00:00Z